^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Q-Force (quercetin)

i
Other names: QB3C, QU995
Associations
Trials
Company:
Quercis Pharma, Temple University
Drug class:
Tyrosine kinase inhibitor, Free radical scavenger, Platelet aggregation inhibitor, Thromboxane synthase inhibitor
Associations
Trials
7ms
Use of a nationwide, patient-powered observational platform to define the landscape of treatment, molecular profiling, and outcomes for fibrolamellar carcinoma. (ASCO 2024)
The most prevalent anti-cancer therapies used were lenvatinib (75% pts exposed) and nivolumab (73% pts) and the most prevalent regimen was gemcitabine/lenvatinib/oxaliplatin (33% of pts). Among repurposed agents, 50% were exposed to quercetin, 44% to celecoxib, and 14% to metformin... Patients with FLC undergo extensive molecular profiling with multiple novel therapeutic regimens being employed in real world practice. Aggregation of raw imaging scans is ongoing for central radiological review to measure depth and duration of response offered by the recorded therapeutic strategies. This dataset is a rich resource available to academic and government researchers to fuel research and define optimal treatment modalities.
Clinical • PD(L)-1 Biomarker
|
Signatera™
|
Opdivo (nivolumab) • gemcitabine • Lenvima (lenvatinib) • oxaliplatin • metformin • Q-Force (quercetin) • celecoxib oral
8ms
polyphenols: Biological Effects of Quercetin in COPD Phase II (clinicaltrials.gov)
P2, N=30, Recruiting, Temple University | Not yet recruiting --> Recruiting
Enrollment open
|
CRP (C-reactive protein)
|
Q-Force (quercetin)
1year
PIM2 kinase regulates TIGIT expression and energy metabolism in NK cells from multiple myeloma patients (IMW 2023)
PIM2 kinase regulates NK cell anti-myeloma activity by modulating TIGIT expression and energy metabolism.
Clinical • IO biomarker
|
IFNG (Interferon, gamma) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • LAMP1 (Lysosomal Associated Membrane Protein 1) • PVR (PVR Cell Adhesion Molecule) • ETS1 (ETS Proto-Oncogene 1)
|
IFNG expression • LAMP1 expression
|
Q-Force (quercetin)
over1year
Protective effect of quercetin against oxidative stress induced by ochratoxin A in hepatocyte (ACS-Fall 2023)
In addition, SOD, GPX, GSR, HO-1, and Nrf2 showed decreased expression at 50 – 250 µM quercetin and OTA at IC50 value. These results suggest that quercetin may alleviate potential OTA-induced liver damage and oxidative stress through reducing cytotoxicity and enhancing the cellular antioxidant defense systems.
Oxidative stress
|
HMOX1 (Heme Oxygenase 1) • CAT (Catalase) • SOD1 (Superoxide Dismutase 1)
|
HMOX1 expression
|
Q-Force (quercetin)
over1year
NATURAL FLAVONOIDS INHIBIT MYELOID NEOPLASM PROLIFERATION BY REGULATING PIM2 KINASE ACTIVITY (EHA 2023)
Kaempferol and Quercetin Dihydrate inhibit proliferation and induce apoptosis of myeloid neoplasms cells. PIM2 is an important target for the development and prognosis of acute myeloid leukemia and MDS. Kaempferol and Quercetin Dihydrate inhibit PIM2 kinase in myeloid neoplasms cells and subsequently participate in NF-κB expression, proliferation and regulation of myeloid neoplasms.
IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • PIM1 (Pim-1 Proto-Oncogene) • GLI2 (GLI Family Zinc Finger 2) • PIM3 (Pim-3 Proto-Oncogene)
|
BCL2 expression • BAX expression • NFKB1 expression
|
AZD1208 • Q-Force (quercetin)
over1year
PIM2 KINASE REGULATES TIGIT EXPRESSION AND ENERGY METABOLISM IN NK CELLS OF PATIENTS WITH MULTIPLE MYELOMA (EHA 2023)
PIM2 kinase regulates NK cell anti-myeloma activity by modulating TIGIT expression and energy metabolism.Figure A.PIM2 was over expressed on NK cells from MM patients, the PIM2 kinase inhibitor improved NK cells function and decreased the expression of TIGIT. B.PIM2 kinase increased TIGIT expression on NK cell surface by up- regulated ETS-1. C.
Clinical • IO biomarker
|
IFNG (Interferon, gamma) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • LAMP1 (Lysosomal Associated Membrane Protein 1) • PVR (PVR Cell Adhesion Molecule) • ETS1 (ETS Proto-Oncogene 1)
|
IFNG expression • PIM2 overexpression
|
Q-Force (quercetin)
2years
Effects of anti-fibrotic standard-of-care and senolytic drugs on senescent human lung fibroblasts (ICLAF 2022)
Senolytics, such as the cocktail quercetin plus dasatinib (D+Q), show impressive effects in experimental models of pulmonary fibrosis... SOC drugs failed to trigger apoptosis in IPF senescent fibroblasts, nintedanib enhanced Bcl-2 levels and pirfenidone triggered the activation of the necroptosis pathway. SOC drugs elevated fibrotic and senescence markers in IPF lung fibroblasts. Together, these data demonstrated the inefficacy of SOC in targeting senescent cells in IPF.Funding: Cedars-Sinai Medical Center
IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • GDF15 (Growth differentiation factor 15) • FASLG (Fas ligand) • CASP3 (Caspase 3)
|
dasatinib • nintedanib • Q-Force (quercetin)
over2years
In-vitro analysis of human sulfotransferase 1A1 (SULT1A1): A potential therapeutic target to overcome drug resistance in breast cancer | Poster Board #3067 (ACS-Fall 2022)
The reduction of SULT1A1 mediated sulfonation of Tamoxifen-metabolites and Fulvestrant in the presence of these inhibitors was assessed using DESI-MS...The structures of each SULT1A1-inhibitor complex were determined to 1.27 Å and 1.51 Å resolution respectively. These high-resolution co-crystal structures facilitate the exploration of the inhibitor binding site for the structure-based design of more potent inhibitors against SULT1A1.
Preclinical
|
ER (Estrogen receptor)
|
ER positive
|
tamoxifen • fulvestrant • Q-Force (quercetin)
3years
[VIRTUAL] Senolytic Cocktail Dasatinib Plus Quercetin Enhances the Antitumor Effect of Senescence-Inducing Radiotherapy in a Preclinical Model of Melanoma (ASTRO 2021)
Tumor cell senescence was determined by the cells’ morphology. Expression of biomarkers for senescence in tumor tissues were determined by senescence associated β-galactosidase (SA-β-Gal) assay, DNA damage (53BP1/ γ-H2AX foci), and qRT-PCR analysis for p21 and p16 genes, and SASP including IL-1b, IL-6, IL-8, TGF-b, TNF-
Preclinical
|
IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • IL1B (Interleukin 1, beta) • TP53BP1 (Tumor Protein P53 Binding Protein 1)
|
dasatinib • Q-Force (quercetin)
3years
Protein disulfide isomerase (PDI) regulates tissue factor (TF) production in inflammatory monocytes and myeloblasts from patients with newly diagnosed AML (DGHO 2021)
Pretreatment or co-incubation with PDI inhibitors also significantly reduced cellular TF activation by antithymocyte globulin or daunorubicin, indicating that downregulation of TF antigen was mainly restricted to the cryptic pool of TF... Our study indicates a complex role for PDI in the regulation of myeloid TF, which includes downregulation of both inducible and constitutive TF production. Thus, targeting PDI might be a promising strategy to prevent or treat AML-associated coagulopathies.
Clinical
|
GLI2 (GLI Family Zinc Finger 2)
|
daunorubicin • Q-Force (quercetin)
4years
Preclinical
|
HER-2 (Human epidermal growth factor receptor 2) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1)
|
HER-2 positive
|
Q-Force (quercetin)
4years
[VIRTUAL] Butterfly pea (Clitoria ternatea Linn.) flower extract prevents MCF7 HER2positive breast cancer cell metastasis invitro (ESMO Asia 2020)
Butterfly pea flower extract has an antimetastatic activity to MCF-7 HER2-positive breast cancer cell line in-vitro. UGM.
Preclinical
|
HER-2 (Human epidermal growth factor receptor 2) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1)
|
HER-2 positive
|
Q-Force (quercetin)
4years
[VIRTUAL] Butterfly pea (Clitoria ternatea Linn.) flower extract prevents MCF7 HER2positive breast cancer cell metastasis invitro (ESMO Asia 2020)
Butterfly pea flower extract has an antimetastatic activity to MCF-7 HER2-positive breast cancer cell line in-vitro. UGM.
Preclinical
|
HER-2 (Human epidermal growth factor receptor 2) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1)
|
HER-2 positive
|
Q-Force (quercetin)